Decision Resources announced today the release of its new report focusing on the rising spread of atherosclerosis -- a common disease characterized by thickening or loss of elasticity of the artery wall, which is a major factor in many cases of cardiovascular disease, comprising coronary heart disease, coronary artery disease, angina, myocardial infarction, ischemic stroke, and peripheral vascular disease. The report found that lifestyle changes such as diet modification, weight reduction, exercise, and smoking cessation are not enough to fight the effects of atherosclerosis, and that there is a need in the market to educate physicians regarding existing drugs that have proven successful in treating Atherosclerosis.
"We found that there is a clear need for physicians to become more aware of existing drugs available to treat atherosclerosis and how to better prescribe them," said Dr. Julie Curran, analyst at Decision Resources. "Our findings indicate that treatment for atherosclerosis is routinely under dosed, while many patients suffering from the disease do not receive any lipid- lowering therapy at all."
The report entitled Atherosclerosis also discusses emerging risk factors, current and emerging therapies and market potential for drugs helping to fight atherosclerosis. Treatment patterns in the major markets (United States, United Kingdom, France, Germany, Italy, Spain, and Japan) are included in the research.
Disease Facts -- Atherosclerosis
The American Heart Association (AHA) estimates that more than 60 million people in the United States have cardiovascular disease, which is responsible for nearly 1 million deaths in the country every year. Until recently, atherosclerosis was perceived as a disease of Western industrialized nations, but since the developing world has increasingly adopted western habits, this perception no longer holds true. The World Health Organization (WHO) reports that cardiovascular disease will be the leading cause of death in developing countries by 2010. The disease burden from atherosclerosis is immense: the AHA estimates that annual direct and indirect costs for treating cardiovascular disease will total $329 billion per year, compared with $157 billion for cancer.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Diseases, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Cardium focuses on indications and issues of interest within the cardiovascular therapeutic area; Atherosclerosis is a Cardium report.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 email@example.com
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Elizabeth Marshall of Decision Resources, +1-781-296-2563,